BioSpace News Archive

Celularity Inc. announced that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with Nasdaq’s continued listing requirements which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it received a notice from the NYSE American LLC dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards.

Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ CCAA ”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) on April 18, 2024.

ReWalk Robotics Ltd. announced that the Board has approved the appointment of Mike Swinford to the Board of Directors, effective April 18, 2024.

Prescient Healthcare Group , a leading biopharma product and portfolio strategy firm, has announced the appointment of two new members to its Board of Directors – Dr. Luke Solon and Debbie Allman – to help shape and drive Prescient’s global mission.

Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research studies published today in the Journal of the American Medical Association (JAMA).

Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.

Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close.

Stuart Therapeutics, Inc. today announced that the company will be presenting its latest research results at both the Association for Research in Vision and Ophthalmology annual meeting, and at two meetings sponsored by the Ophthalmology Innovation Source (OIS) in early May.